Is CL stock a buy right now?

Opinions differ. Bulls cite strong brands, margin momentum, and a growing pet nutrition business. Bears point to a premium multiple and high leverage. With earnings on January 30, many investors may wait for guidance on organic sales and 2026 targets. Price action around $75 to $78 could shape near-term risk-reward.

What is Morgan Stanley’s view and target on CL stock?

Morgan Stanley keeps an overweight on CL stock and named it a top pick for 2026 with an $87 target, focusing on resilient demand, pricing, and margin expansion potential. That lines up with a broader Buy skew and roughly $88 consensus. The January 30 update will be key to support this view into 2026.

Why do some analysts flag valuation risk for CL stock?

Some models say CL stock trades above fair value, with P/E near 22 to 23 times versus an 18.8x fair ratio. Supporters argue quality and cash flow deserve a premium. Skeptics note high leverage and liquidity below 1, which reduce flexibility if growth or pricing softens in 2026.

What are the key dates for CL stock in January 2026?

CL stock’s critical near-term date is January 30, when Colgate-Palmolive reports Q4 results and provides guidance. Investors will scrutinize organic sales, pricing, cost inflation, and cash returns. The commentary on 2026 growth and margins could be the main driver for the stock’s next move.

Global Market Insights

CL Stock Today: January 10 – Morgan Stanley Top Pick vs Valuation Risk

ByDanny Kontos January 10, 2026January 10, 2026

CL stock is in focus today as we weigh a fresh bull call against valuation concerns. Morgan Stanley named CL a 2026 top pick with an overweight rating and an $87 target, while others flag a premium to fair value. Shares recently traded near $76.93 with a 22.8x P/E and a 2.5% dividend yield. With Q4 results due January 30, investors want clarity on organic sales growth, pricing power, and 2026 earnings outlook. We break down the setup for CL stock and the near-term trading drivers.